Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

Journal of Clinical Investigation

Volumn 116, Issue 10, 2006, Pages 2695-2706

  Engelman, Jeffrey A ^a,b,c   Mukohara, Toru ^d   Zejnullahu, Kreshnik ^d   Lifshits, Eugene ^e   Borrás, Ana M ^d   Gale, Christopher Michael ^c   Naumov, George N ^e   Yeap, Beow Y ^a   Jarrell, Emily ^c   Sun, Jason ^d   Tracy, Sean ^d   Zhao, Xiaojun ^d   Heymach, John V ^f   Johnson, Bruce E ^d,g   Cantley, Lewis C ^b,c,h   Jänne, Pasi A ^d,g  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h HARVARD INSTITUTES OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CL 387785; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ALLELE; ARTICLE; CANCER CELL CULTURE; DRUG INHIBITION; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ALLELES; ANIMALS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; MICE; MUTATION, MISSENSE; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; RNA INTERFERENCE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749435816     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI28656     Document Type: Article

References (55)

1. Rusch, V., et al. 1997. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res. 3:515-522.
2. Fontanini, G., et al. 1998. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin. Cancer Res. 4:241-249.
3. Brabender, J., et al. 2001. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 7:1850-1855.
4. Shepherd, F.A., et al. 2005. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353:123-132.
5. Fukuoka, M., et al. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21:2237-2246.
6. Kris, M.G., et al. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA. 290:2149-2158.
7. Perez-Soler, R., et al. 2004. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22:3238-3247.
8. Paez, J.G., et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497-1500.
9. Lynch, T.J., et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350:2129-2139.
10. Pao, W., et al. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. U. S. A. 101:13306-13311.
11. Mitsudomi, T., et al. 2005. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23:2513-2520.
12. Han, S.W., et al. 2005. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23:2493-2501.
13. Takano, T., et al. 2005. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 23:6829-6837.
14. Cappuzzo, F., et al. 2005. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97:643-655.
15. Amann, J., et al. 2005. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65:226-235.
16. Tracy, S., et al. 2004. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64:7241-7244.
17. Bianco, R., et al. 2003. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene. 22:2812-2822.
18. She, Q.B., et al. 2005. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 8:287-297.
19. Baselga, J., et al. 2005. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer. J. Clin. Oncol. 23:5323-5333.
20. Gorre, M.E., Ellwood-Yen, K., Chiosis, G., Rosen, N., and Sawyers, C.L. 2002. BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood. 100:3041-3044.
21. Antonescu, C.R., et al. 2005. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin. Cancer Res. 11:4182-4190.
22. Pao, W., et al. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73.
23. Kwak, E.L., et al. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. U. S. A. 102:7665-7670.
24. Kobayashi, S., et al. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352:786-792.
25. Kobayashi, S., et al. 2005. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 65:7096-7101.
26. Engelman, J.A., et al. 2005. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. U. S. A. 102:3788-3793.
27. Fujimoto, N., et al. 2005. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. 65:11478-11485.
28. Ricci, C., et al. 2002. Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Res. 62:5995-5998.
29. Albanell, J., et al. 2002. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol. 20:110-124.
30. Mukohara, T., et al. 2005. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J. Natl. Cancer Inst. 97:1185-1194.
31. Janmaat, M.L., Kruyt, F.A., Rodriguez, J.A., and Giaccone, G. 2003. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 9:2316-2326.
32. Brehmer, D., et al. 2005. Cellular targets of gefitinib. Cancer Res. 65:379-382.
33. Fabian, M.A., et al. 2005. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 23:329-336.
34. Janne, P.A., et al. 2006. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening. Clin. Cancer Res. 12:751-758.
35. Samuels, Y., et al. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science. 304:554.
36. Samuels, Y., et al. 2005. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell. 7:561-573.
37. Isakoff, S.J., et al. 2005. Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65:10992-11000.
38. Kang, S., Bader, A.G., and Vogt, P.K. 2005. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. U. S. A. 102:802-807.
39. Greulich, H., et al. 2005. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2:e313.
40. Bell, D.W., et al. 2005. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat. Genet. 37:1315-1316.
41. Toyooka, S., Kiura, K., and Mitsudomi, T. 2005. EGFR mutation and response of lung cancer to gefitinib. N. Engl. J. Med. 352:2136; author reply 2136.
42. Tabone, S., et al. 2005. KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochim. Biophys. Acta. 1741:165-172.
43. Debiec-Rychter, M., et al. 2005. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology. 128:270-279.
44. Hochhaus, A., et al. 2002. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 16:2190-2196.
45. Mellinghoff, I.K., et al. 2005. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353:2012-2024.
46. Slamon, D.J., et al. 1989. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 244:707-712.
47. Levine, R.L., et al. 2005. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 7:387-397.
48. Nagata, Y., et al. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6:117-127.
49. Jackman, D.M., et al. 2006. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin. Cancer Res. 12:3908-3914.
50. Riely, G.J., et al. 2006. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin. Cancer Res. 12:839-844.
51. Fujishita, T., et al. 2003. Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel. Oncology. 64:399-406.
52. Namikawa, K., et al. 2000. Akt/protein kinase B prevents injury-induced motoneuron death and accelerates axonal regeneration. J. Neurosci. 20:2875-2886.
53. Zhao, J.J., et al. 2003. Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell. 3:483-495.
54. Zhao, X., et al. 2005. Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res. 65:5561-5570.
55. Sirotnak, F.M., Zakowski, M.F., Miller, V.A., Scher, H.I., and Kris, M.G. 2000. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6:4885-4892.